Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
289.12(c) 292.04(c) 296.86(c) 297.34(c) 296.04(c) Last
3 408 984 1 706 165 1 273 598 1 206 670 1 219 386 Volume
-5.22% +1.01% +1.65% +0.16% -0.44% Change
More quotes
Financials (USD)
Sales 2018 12 953 M
EBIT 2018 6 629 M
Net income 2018 4 490 M
Debt 2018 701 M
Yield 2018 -
Sales 2019 13 335 M
EBIT 2019 7 157 M
Net income 2019 4 864 M
Finance 2019 3 801 M
Yield 2019 -
P/E ratio 2018 13,82
P/E ratio 2019 12,61
EV / Sales2018 4,88x
EV / Sales2019 4,40x
Capitalization 62 467 M
More Financials
Company
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment... 
Sector
Pharmaceuticals
Calendar
06/28 | 02:00pmSpecial Situation
More about the company
Surperformance© ratings of Biogen
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN
06/22BIOGEN : to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 20..
AQ
06/21BIOGEN : Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF..
AQ
06/21BIOGEN : Researchers from Biogen Report Details of New Studies and Findings in t..
AQ
06/20REGENERON PHARMACEUTICALS : Decibel raises $55M in series C, names Scangos chair..
AQ
06/19Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2..
GL
06/18Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM..
GL
06/15BIOGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/15BIOGEN : Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF..
AQ
06/15BIOGEN : Enhances Commitment to SMA Research with Data Presented at Annual SMA C..
AQ
06/14BIOGEN : Studies from Biogen Reveal New Findings on Protein Kinase C [Investigat..
AQ
More news
Sector news : Biopharmaceuticals
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN 
BIOGEN - 02/26
Close to an important medium term support level
BUY
BIOGEN IDEC  - 2014
Back on a stimulating support
BUY
More Strategies
Latest Tweets
10:36aBiogen $BIIB Cut to “Hold” at BidaskClub  
06/22Want the latest upgrades & downgrades for $OXLC $GILD $BIIB $KEYN $HGSI? .. 
06/21Former $BIIB CEO George Scangos said a couple years ago the company is spendi..
1
06/20Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
4
06/20Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday: Yeste.. 
More tweets
Qtime:158
News from SeekingAlpha
06/22BIOGEN : High Competitive Threats, But A Promising Pipeline 
06/19Biogen webcast of ischemic stroke activities June 28 
06/19ALZHEIMER'S DISEASE : A History Of Drug Failures 
06/19PTC Therapeutics Surges On Positive Outcome From Rare Disease Study 
06/18PTC Therapeutics' risdiplam shows positive effect in SMA study; shares up 36%.. 
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 349 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Michael D. Ehlers Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN-7.07%62 467
CSL LIMITED40.46%66 254
ALEXION PHARMACEUTICALS6.67%28 384
GRIFOLS9.89%19 298
BIOMARIN PHARMACEUTICAL11.06%17 500
CELLTRION HEALTHCARE CO LTD--.--%13 759